ATRenew Inc. Sponsored ADR (RERE.US) Q3 revenue increased by 24% year-on-year, turning a loss into a profit.
"(RERE.US) announced its third quarter performance."
ATRenew Inc. Sponsored ADR (RERE.US) announced its third-quarter performance. The data shows that the company had a Q3 revenue of 4.051 billion yuan, a year-on-year increase of 24.4%, exceeding market expectations; net profit was 17.9 million yuan, compared to a net loss of 44.2 million yuan in the same period last year; basic and diluted earnings per share were 0.11 yuan, compared to a loss per share of 0.27 yuan in the same period last year.
By business segment, product revenue was 3.672 billion yuan, a year-on-year increase of 25.6%; service revenue was 3.79 billion yuan, a year-on-year increase of 13.9%.
The number of consumer goods transactions was 9.1 million, compared to 8.2 million in the same period last year.
Looking ahead, ATRenew Inc. Sponsored ADR expects fourth-quarter revenue to be between 4.74 billion yuan and 4.84 billion yuan, a year-on-year increase of 22.4% to 24.9%.
Related Articles

Medicalsystem Biotechnology (300439.SZ) subsidiary has obtained multiple medical device registration certificates.

C-MER MEDICAL (03309) spent HK$314,800 to repurchase 160,000 shares on September 17.
.png)
Ping An Insurance (02318): Completion of long-term service plan for stock purchase in 2025.
Medicalsystem Biotechnology (300439.SZ) subsidiary has obtained multiple medical device registration certificates.

C-MER MEDICAL (03309) spent HK$314,800 to repurchase 160,000 shares on September 17.

Ping An Insurance (02318): Completion of long-term service plan for stock purchase in 2025.
.png)